Contact
searchSearch
HMP Global

Hepatocellular Carcinoma Topic Center

Featured

Riccardo Lencioni, MD, University of Pisa School of Medicine
Videos
Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS
01/23/2024
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares...
01/23/2024
Oncology
From Oncology
Dan Brown
Liver Metastatic Disease: 2022 Year in Review
Daniel Brown, MD, FSIR reviews noteworthy 2022 studies on liver metastatic disease at the Symposium on Clinical Interventional Oncology.
01/04/2023
Riad Salem, MD, MBA
HCC: 2022 Year in Review
Riad Salem, MD, MBA presents notable studies from 2022 at the Symposium on Clinical Interventional Oncology.
01/01/2023
Brennan Cronquist
CIO2022 Highlights
Irreversible Electroporation vs Radiofrequency Ablation for HCC
10/27/2022
B. Cronquist, 4th year medical student at the George Washington University School of Medicine and Health Sciences, discusses his CIO2022 abstract, "CIO 2022-6 Irreversible Electroporation versus Radiofrequency Ablation as a Treatment Option...
B. Cronquist, 4th year medical student at the George Washington University School of Medicine and Health Sciences, discusses his CIO2022 abstract, "CIO 2022-6 Irreversible Electroporation versus Radiofrequency Ablation as a Treatment Option...
B. Cronquist, 4th year medical...
10/27/2022
IO Learning
Dr Edward Kim
CIO2022 Highlights
Edward Kim, MD, FSIR, Discusses the Updated Clinical and Dosimetric Recommendations for Y-90 Glass Microspheres in HCC
10/26/2022
Dr Edward Kim discusses his CIO2022 abstract, "Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma."
Dr Edward Kim discusses his CIO2022 abstract, "Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma."
Dr Edward Kim discusses his...
10/26/2022
IO Learning
News
Adding Radiation to Systemic Therapy Extends Overall Survival for Patients with Advanced Liver Cancer
10/24/2022
American Society for Radiation Oncolo...
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial...
10/24/2022
IO Learning
CIO 2022-1 Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3
Purpose: Locoregional therapies such as transarterial chemoembolization (TACE) are the most common treatments for patients with intermediate-stage hepatocellular carcinoma (HCC). Although...
10/18/2022
CIO 2022-3 Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma
Purpose: The TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to update the clinical and dosimetric recommendations for the treatment of unresectable hepatocellular carcin...
10/18/2022
CIO 2022-6 Irreversible Electroporation versus Radiofrequency Ablation as a Treatment Option in Hepatocellular Carcinoma
Purpose: In the United States, hepatocellular carcinoma (HCC) has an incidence of 7.7 per 100,000, which has steadily increased from 1992, when there was an incidence of 4.1 per 100,000. ...
10/18/2022
CIO 2022-7 Irreversible Electroporation versus Microwave Ablation as a Treatment Option in Hepatocellular Carcinoma
Purpose: In the United States, hepatocellular carcinoma (HCC) has an incidence of 7.7 per 100,000 and is the most common cause of primary liver cancer worldwide. The gold-standard treatme...
10/18/2022
CIO 2022-8 Predictors of Overall Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
Purpose: To evaluate predictors of overall survival in patients with hepatocellular carcinoma (HCC) treated with lipiodol transarterial chemoembolization (cTACE).
10/18/2022

Subscribe

IO Learning Newsletter

News

News
Adding Radiation to Systemic Therapy Extends Overall Survival for Patients with Advanced Liver Cancer
10/24/2022
American Society for Radiation Oncolo...
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial...
10/24/2022
IO Learning
News
New technology aims toward earlier detection of hepatocellular carcinoma
08/04/2022
University of California, Los Angeles (UCLA), Health Sciences Primary liver cancer, the third-leading cause of cancer-related death worldwide, takes more than 30,000 lives in the United States each year. The high mortality rates can be...
University of California, Los Angeles (UCLA), Health Sciences Primary liver cancer, the third-leading cause of cancer-related death worldwide, takes more than 30,000 lives in the United States each year. The high mortality rates can be...
University of California, Los...
08/04/2022
IO Learning
News
HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies
06/03/2022
Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy
Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy
Company Continues to Build as It...
06/03/2022
IO Learning
News
Fluidx Medical Reveals New Embolic Platform for Internal Bleeding, Tumor Treatment, and Other Uses
11/30/2023
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx...
11/30/2023
Vascular Disease Management
News
Radiation Therapy May Be Potential Heart Failure Treatment
11/28/2023
The study suggests that low-dose radiation therapy improves heart function, at least in part, by reducing the number of inflammatory immune cells in the heart muscle.
The study suggests that low-dose radiation therapy improves heart function, at least in part, by reducing the number of inflammatory immune cells in the heart muscle.
The study suggests that low-dose...
11/28/2023
Cath Lab Digest
News
Canon Medical Introduces Alphenix Sky 12 HD Interventional System
09/12/2023
Tustin, CA (12 September 2023) — Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD...
Tustin, CA (12 September 2023) — Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD...
Tustin, CA (12 September 2023) —...
09/12/2023
IO Learning
News
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting
09/11/2023
New York, NY (11 September 2023) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the details of an oral...
New York, NY (11 September 2023) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the details of an oral...
New York, NY (11 September 2023)...
09/11/2023
IO Learning
News
Boston Scientific Receives 510(k) Clearance for Expanded Cryoablation System
08/25/2023
Marlborough, MA. (25 August 2023) — Boston Scientific has received 510(k) clearance for expanded indication of the VISUAL ICE cryoablation system. The clearance grants this device an indication expansion to now...
Marlborough, MA. (25 August 2023) — Boston Scientific has received 510(k) clearance for expanded indication of the VISUAL ICE cryoablation system. The clearance grants this device an indication expansion to now...
Marlborough, MA. (25 August...
08/25/2023
IO Learning
News
Delcath Systems Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
08/21/2023
New York, NY. (21 August 2023) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug...
New York, NY. (21 August 2023) — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug...
New York, NY. (21 August 2023)...
08/21/2023
IO Learning
News
HMP Global Earns Healthcare Industry Top Workplaces Award for Company Culture, Employee Satisfaction
08/18/2023
Malvern, PA (18 August 2023) — HMP Global, the leading omnichannel events and education company, is one of only 111 companies nationwide to earn a 2023 Healthcare Industry Top Workplaces award, its fifth award this year based on employee...
Malvern, PA (18 August 2023) — HMP Global, the leading omnichannel events and education company, is one of only 111 companies nationwide to earn a 2023 Healthcare Industry Top Workplaces award, its fifth award this year based on employee...
Malvern, PA (18 August 2023)...
08/18/2023
IO Learning
News
Siemens Healthineers Announces Partnership With SSM Health
08/14/2023
Erlangen, Germany (14 August 2023) —SSM Health and Siemens Healthineers have announced a new 10-year strategic partnership agreement focused on expanding access to high-quality care and training the next generation of health care...
Erlangen, Germany (14 August 2023) —SSM Health and Siemens Healthineers have announced a new 10-year strategic partnership agreement focused on expanding access to high-quality care and training the next generation of health care...
Erlangen, Germany (14 August...
08/14/2023
IO Learning
News
Interventional Oncology Accreditation Program IASIOS Continues to Reach new Heights
08/11/2023
Vienna, Austria (11 August 2023) — The only accreditation system of its kind has nearly tripled its network of esteemed interventional oncology centers worldwide since launching in 2021.The International Accreditation System...
Vienna, Austria (11 August 2023) — The only accreditation system of its kind has nearly tripled its network of esteemed interventional oncology centers worldwide since launching in 2021.The International Accreditation System...
Vienna, Austria (11 August 2023)...
08/11/2023
IO Learning
News
Accuray Receives FDA 510(k) Clearance for its VitalHold™ on the Radixact® System
08/10/2023
Madison, WI (10 August 2023) — Accuray Incorporated has announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its VitalHold™* breast package on...
Madison, WI (10 August 2023) — Accuray Incorporated has announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its VitalHold™* breast package on...
Madison, WI (10 August 2023)...
08/10/2023
IO Learning

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use